Novartis Oncology

Type: Company

Name: Novartis Oncology

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Pink ribbons don't do much for advanced breast cancer sufferers, survey finds

A survey of women living with advanced or metastatic breast cancer found that many feel left out by breast cancer advocacy groups focused on prevention, early detection and research for a cure.Novartis Oncology surveyed 1,300 women with the disease in ... [Published Medical Marketing And Media - May 21 2013]

Entities: Breast Cancer, Novartis AG, Novartis Oncology, Afinitor, Femara

First reported May 21 2013 - Updated May 21 2013 - 1 reports

âWomen with adv breast cancer feel left out of cancer movementâ

women living with advanced or metastatic breast cancer feel isolated and left out of the broader breast cancer movement. The new global "Count Us, Know Us, Join Us" survey sponsored by Novartis Oncology finds that despite breast cancer being the most ... [Published India Infoline - May 21 2013]

Entities: Breast Cancer, Cancer, Metastatic

First reported May 16 2013 - Updated May 16 2013 - 1 reports

M.O.R.E. Network Event for People Living with Advanced Breast Cancer

Categories Education/Campus HealthTags advanced breast cancer metastatic breast cancer Thursday, May 23 6:30p to 8:30pTexas Health Resource University Building Dallas, TXNorth Texas Cancer Support Community and Novartis Oncology are hosting a M.O.R.E. ... [Published GuideLive - May 16 2013]

Entities: Breast Cancer, Metastatic, Novartis Oncology, Dallas (Texas, United States), Cancer

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis

Disclosures: : Novartis Oncology, Celgene Corporation, Medarex Pharmaceuticals (RF); : Agennix, Boehringer Ingelheim, Genentech, Lilly, Teva (C/A).Objectives. Disparity exists between patients with lung cancer enrolled in clinical trials and patients ... [Published The Oncologist - May 02 2013]

Entities: non-small cell lung cancer, Patient, Pemetrexed, bevacizumab, docetaxel

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Kidney Cancer Association European International Symposium Webcast

Outreach to physicians and scientists extended globally from Budapest, Hungary. Paula E. Bowen The will be webcast live from Budapest, May 3rd and 4th, 2013. Bringing together key individuals and representatives from leading laboratories and centers working ... [Published PRWeb - Apr 30 2013]

Entities: Kidney Cancer Association, Budapest, Oncology

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Gleevec

Leukaemia drug prices "unsustainable" say cancer experts

Study says patients may not be able to afford effective treatmentThe escalating cost of drugs to treat chronic myeloid leukaemia (CML) mean some patients may not be able to afford effective treatment, claims a prominent group of cancer professionals.Around ... [Published PMLive - Apr 29 2013]

Entities: Patient, Gleevec, Drugs, Leukaemia, Cancer

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Endocyte Inc

Endocyte brings in senior figures from BMS and Amgen

Appoints Torsten Hoof and Ulf Staginnus as company prepares to launch cancer drugsEndocyte has made two senior additions to its European team, bringing in Torsten Hoof from Bristol-Myers Squibb (BMS) as VP and general manager, Europe, and Amgen's Ulf ... [Published PMLive - Apr 29 2013]

Entities: Endocyte Inc, Amgen Inc, David Meek, Cancer

First reported Apr 01 2013 - Updated Apr 02 2013 - 2 reports

Novartis' Patent Denial

Home » Blogs » Earlier today, the Supreme Court of India denied the patent of Novartis' (NVS) billion dollar drug Glivec citing the followingRelated Biotechnology, Pharmaceutical and Healthcare NewsPatent denied despite global recognition of Glivec as ... [Published BioPortfolio - Apr 01 2013]

Entities: Patent, Novartis AG, Gleevec

First reported Mar 23 2013 - Updated Mar 23 2013 - 1 reports

10th Annual Strategic Alliance Management Congress

6th8th May 2013 Now in its 10th year, the program features three days of interactive presentations, roundtable sessions, panel discussions and dedicated networking to provide the connections and insights needed to keep your partnerships moving forwar ... [Published Pharmalicensing - Mar 23 2013]

Entities: RUSNANO Russian Corporation of Nanotechnologies, Vantage Partners, Integrated Project Management Co Inc, VirtualScopics Inc

Quotes

...population where there remains an unmet need," said Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis Oncology. "Everolimus works differently than any currently available treatment for HER2 positive breast cancer, and these results support its potential expanded role in advanced breast cancer."

Novartis drug Afinitor extends time without disease progression in women with HER2+ breast cancer [Published PharmaBiz - May 20 2013]

"We believe the unsustainable drug prices in CML and cancer may be causing harm to patients," say the authors. "Advocating for lower drug prices is a necessity to save the lives of patients who cannot afford them."

Leukaemia drug prices "unsustainable" say cancer experts [Published PMLive - Apr 29 2013]

Ron Ellis, president and CEO of Endocyte, explained the latest appointments: "Dr Hoof brings with him extensive knowledge of the European marketplace and success in launching high-profile products, including major cancer therapeutics. Mr Staginnus' expertise and track record with major biotech companies will provide us with the necessary leadership for product pricing and market access."

Endocyte brings in senior figures from BMS and Amgen [Published PMLive - Apr 29 2013]

...identifying the underlying cause of disease pathways," said Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis Oncology. "This Breakthrough Therapy designation will allow us to collaborate more closely with the FDA and potentially to expedite the availability of an important new treatment option for patients with ALK+ NSCLC."

US FDA grants Breakthrough Therapy designation to Novartis' LDK378 for the treatment of ALK+ NSCLC [Published PharmaBiz - Mar 16 2013]

More Content

sort by: Date \| Relevance
Pink ribbons don't do much for advanced breast ... [Published Medical Marketing And Media - May 21 2013]
âWomen with adv breast cancer feel left out of ... [Published India Infoline - May 21 2013]
Largest-ever global survey of 1,273 women in 12... [Published PR Newswire: General Business - May 21 2013]
Novartis drug Afinitor extends time without dis... [Published PharmaBiz - May 20 2013]
Novartis drug Afinitor(R) significantly extende... [Published Reuters - May 17 2013]
Novartis drug Afinitor® significantly extended ... [Published Quoteline - May 17 2013]
Novartis drug Afinitor® significantly extended ... [Published TD Ameritrade - May 17 2013]
M.O.R.E. Network Event for People Living with A... [Published GuideLive - May 16 2013]
Conquer Cancer Foundation Recognizes Outstandin... [Published Oncology Business Review - May 07 2013]
Bumps Along the Way to Develop Prostate Cancer ... [Published Oncology Times - May 04 2013]
Real-World Effectiveness of Systemic Agents App... [Published The Oncologist - May 02 2013]
MM&M Awards 2013: Judging Panel [Published Medical Marketing And Media - May 01 2013]
Kidney Cancer Association European Internationa... [Published PRWeb - Apr 30 2013]
Leukaemia drug prices "unsustainable" say cance... [Published PMLive - Apr 29 2013]
Endocyte brings in senior figures from BMS and ... [Published PMLive - Apr 29 2013]
Novartis celebrates a decade of helping Filipin... [Published Philippine Star - Apr 18 2013]
Novartis' Patent Denial [Published BioPortfolio - Apr 01 2013]
Novartis' Patent Denial [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 01 2013]
10th Annual Strategic Alliance Management Congress [Published Pharmalicensing - Mar 23 2013]
US FDA grants Breakthrough Therapy designation ... [Published PharmaBiz - Mar 16 2013]
US FDA approves Novartis' drug Exjade for chron... [Published PharmaBiz - Jan 25 2013]
Phase III data shows Novartis drug Afinitor ben... [Published PharmaBiz - Jan 12 2013]
European Commission approves Novartis' Exjade f... [Published PharmaBiz - Dec 24 2012]
US FDA approves Novartis' Signifor for first me... [Published PharmaBiz - Dec 17 2012]
Child stirs hope of cancer milestone [Published Calcutta Telegraph - Dec 11 2012]
CHMP recommends Novartis drug Exjade to treat N... [Published PharmaBiz - Nov 19 2012]
US FDA advisory committee recommends approval o... [Published PharmaBiz - Nov 09 2012]
European Commission approves Novartis' Votubia ... [Published PharmaBiz - Nov 06 2012]
European Commission Approves New Label for Nova... [Published PRWeb - Oct 07 2012]
EMA committee recommends approval of Novartis d... [Published PharmaBiz - Sep 24 2012]